Pulmatrix (PULM) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 07, 2023
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-36199
Entity Registrant Name	PULMATRIX, INC.
Entity Central Index Key	0001574235
Entity Tax Identification Number	46-1821392
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	36 Crosby Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	(781)
Local Phone Number	357-2333
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PULM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,652,285
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	99 Hayden Avenue
Entity Address, Address Line Two	Suite 390
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,791	$ 35,628
Restricted cash	153	153
Accounts receivable	418	1,298
Prepaid expenses and other current assets	1,019	1,068
Total current assets	27,381	38,147
Property and equipment, net	279	235
Operating lease right-of-use asset	277	710
Long-term restricted cash	1,472	1,472
Other long-term assets	1,984	389
Total assets	31,393	40,953
Current liabilities:
Accounts payable	929	1,188
Accrued expenses and other current liabilities	1,201	1,638
Operating lease liability	358	857
Deferred revenue	1,109	1,339
Total current liabilities	3,597	5,022
Deferred revenue, net of current portion	4,347	4,822
Total liabilities	7,944	9,844
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 and 3,639,185 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital	305,189	304,585
Accumulated deficit	(281,740)	(273,476)
Total stockholders’ equity	23,449	31,109
Total liabilities and stockholders’ equity	$ 31,393	$ 40,953

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	3,652,285	3,639,185
Common stock, shares outstanding	3,652,285	3,639,185
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	6,746	6,746
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 1,844	$ 1,331	$ 3,343	$ 2,491
Operating expenses
Research and development	4,165	4,337	8,039	8,486
General and administrative	1,670	1,553	3,880	3,527
Total operating expenses	5,835	5,890	11,919	12,013
Loss from operations	(3,991)	(4,559)	(8,576)	(9,522)
Other income (expense)
Interest income	236	15	458	16
Other expense, net	(61)	(51)	(146)	(62)
Total other income (expense), net	175	(36)	312	(46)
Net loss	$ (3,816)	$ (4,595)	$ (8,264)	$ (9,568)
Net loss per share attributable to common stockholders basic	$ (1.04)	$ (1.36)	$ (2.26)	$ (2.87)
Net loss per share attributable to common stockholders diluted	$ (1.04)	$ (1.36)	$ (2.26)	$ (2.87)
Weighted average common shares outstanding basic	3,652,285	3,372,090	3,651,531	3,334,891
Weighted average common shares outstanding diluted	3,652,285	3,372,090	3,651,531	3,334,891

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 1,081		$ 301,008	$ (254,640)	$ 47,449
Balance, shares at Dec. 31, 2021	1,830	3,222,037
Stock-based compensation			281		281
Net loss				(4,973)	(4,973)
Conversion of preferred stock to common stock	$ (541)		541
Conversion of preferred stock to common stock, shares	(915)	76,250
Adjustment due to reverse stock split
Adjustment due to reverse stock split, shares		12,635
Balance at Mar. 31, 2022	$ 540		301,830	(259,613)	42,757
Balance, shares at Mar. 31, 2022	915	3,310,922
Balance at Dec. 31, 2021	$ 1,081		301,008	(254,640)	47,449
Balance, shares at Dec. 31, 2021	1,830	3,222,037
Net loss					(9,568)
Balance at Jun. 30, 2022			302,647	(264,208)	38,439
Balance, shares at Jun. 30, 2022		3,387,172
Balance at Mar. 31, 2022	$ 540		301,830	(259,613)	42,757
Balance, shares at Mar. 31, 2022	915	3,310,922
Stock-based compensation			277		277
Net loss				(4,595)	(4,595)
Conversion of preferred stock to common stock	$ (540)		540
Conversion of preferred stock to common stock, shares	(915)	76,250
Balance at Jun. 30, 2022			302,647	(264,208)	38,439
Balance, shares at Jun. 30, 2022		3,387,172
Balance at Dec. 31, 2022			304,585	(273,476)	31,109
Balance, shares at Dec. 31, 2022		3,639,185
Issuance of common stock, net of issuance costs			53		53
Issuance of common stock, net of issuance costs, shares		13,100
Stock-based compensation			296		296
Net loss				(4,448)	(4,448)
Balance at Mar. 31, 2023			304,934	(277,924)	27,010
Balance, shares at Mar. 31, 2023		3,652,285
Balance at Dec. 31, 2022			304,585	(273,476)	31,109
Balance, shares at Dec. 31, 2022		3,639,185
Net loss					(8,264)
Balance at Jun. 30, 2023			305,189	(281,740)	23,449
Balance, shares at Jun. 30, 2023		3,652,285
Balance at Mar. 31, 2023			304,934	(277,924)	27,010
Balance, shares at Mar. 31, 2023		3,652,285
Stock-based compensation			255		255
Net loss				(3,816)	(3,816)
Balance at Jun. 30, 2023			$ 305,189	$ (281,740)	$ 23,449
Balance, shares at Jun. 30, 2023		3,652,285

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (8,264)	$ (9,568)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	64	82
Amortization of operating lease right-of-use asset	777	686
Stock-based compensation	551	558
Changes in operating assets and liabilities:
Accounts receivable	880	(578)
Prepaid expenses and other current assets	49	(1,271)
Other long-term assets	(1,595)	(368)
Accounts payable	(309)	51
Accrued expenses and other current liabilities	(437)	377
Operating lease liability	(843)	(586)
Deferred revenue	(705)	(89)
Net cash used in operating activities	(9,832)	(10,706)
Cash flows from investing activities:
Purchases of property and equipment	(58)	(77)
Net cash used in investing activities	(58)	(77)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	53
Preferred stock issuance costs		(152)
Net cash provided by (used in) financing activities	53	(152)
Net decrease in cash, cash equivalents and restricted cash	(9,837)	(10,935)
Cash, cash equivalents and restricted cash — beginning of period	37,253	55,465
Total cash, cash equivalents and restricted cash	27,416	44,530
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	25,791	42,905
Restricted cash	153	153
Long-term restricted cash	1,472	1,472
Supplemental disclosures of non-cash investing and financing information:
Operating lease right-of-use asset obtained in exchange for operating lease obligation	344
Fixed asset purchases in accounts payable	50
Conversion of preferred stock to common stock		$ 1,081

Organization

Organization	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Pulmatrix, Inc. (the “Company”) was incorporated in 2013 as a Delaware corporation. The Company is a clinical-stage biopharmaceutical company focused on the development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE ™ ™

Summary of Significant Accounti

Summary of Significant Accounting Policies and Recent Accounting Standards	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Recent Accounting Standards	2. Summary of Significant Accounting Policies and Recent Accounting Standards Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 30, 2023 (the “Annual Report”). The financial information as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2022 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, incremental borrowing rate, and accounting for income taxes and the related valuation allowance. Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three and six months ended June 30, 2023, revenue from one customer accounted for 100 99 100 Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as set forth below, the Company did not adopt any new accounting pronouncements during the six months ended June 30, 2023 that had a material effect on its condensed consolidated financial statements. In June 2016, the FASB issued Accounting Standards Update (“ASU”) ASU 2016-13, Financial Instruments—Credit Losses (Topic 326)—Measurement of Credit Losses on Financial Instruments January 1, 2023 As of June 30, 2023, there are no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments As of June 30, 2023 and December 31, 2022, the Company did not hold any financial assets or liabilities that were measured at fair value on a recurring or nonrecurring basis. During the six months ended June 30, 2023, there were no transfers between Level 1, Level 2 and Level 3.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2023
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2023 December 31, 2022 Insurance $ 496 $ 286 Clinical and consulting 132 517 Software and hosting costs 119 99 Other 272 166 Total prepaid expenses and other current assets $ 1,019 $ 1,068

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: Schedule of Property and Equipment June 30, 2023 December 31, 2022 Laboratory equipment $ 1,835 $ 1,827 Leasehold improvements 664 664 Computer equipment 262 275 Office furniture and equipment 217 217 Capital in progress 100 - Total property and equipment 3,078 2,983 Less accumulated depreciation and amortization (2,799 ) (2,748 ) Property and equipment, net $ 279 $ 235 Depreciation and amortization expense for the six months ended June 30, 2023 and 2022 was $ 64 81

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities June 30, 2023 December 31, 2022 Wages and incentives $ 746 $ 1,130 Clinical and consulting 287 475 Legal and patents 74 - Other 94 33 Total accrued expenses and other current liabilities $ 1,201 $ 1,638

Significant Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Significant Agreements	7. Significant Agreements Development and Commercialization Agreement with Cipla Technologies LLC (“Cipla”) On April 15, 2019, the Company entered into a Development and Commercialization Agreement (the “Cipla Agreement”) with Cipla for the co-development and commercialization, on a worldwide exclusive basis, of PUR1900, the Company’s inhaled iSPERSE ™ The Company received a non-refundable upfront payment of $ 22.0 ™ Pursuant to the Amendment, the Company and Cipla will each initially be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). Upon the achievement of each development milestone set forth in the table below, Cipla will reimburse the Company an amount equal to 10% of the cumulative aggregate Direct Costs incurred (each reimbursement referred to as a “Holdback Payment”), potentially bringing the sharing of Direct Costs to a 50/50 basis. If a development milestone is not achieved, the respective Holdback Payment will continue to aggregate and be reimbursed by Cipla to the Company if the Company achieves the subsequent development milestone for that trial set forth in the table below. The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis. Phase 2b Development Plan – Development Milestones Development Milestone Milestone Date 25% of patients enrolled in Phase 2b clinical study are dosed June 30, 2023 Company delivers summary of key efficacy and safety data to include FEV 1 June 30, 2024 Phase 3 Development Plan – Development Milestones Development Milestone Milestone Date 25% of patients enrolled in Phase 3 clinical study dosed To be proposed by JSC Company delivers Topline Results to the JSC To be proposed by JSC The Prescription Drug User Fee Act To be proposed by JSC The first Phase 2b development milestone was not achieved by June 30, 2023, in part due to delays in regulatory approval in certain foreign jurisdictions. Accordingly, the associated cumulative aggregated Holdback Payment could be reimbursed by Cipla to the Company if the Company achieves the subsequent development milestone by June 30, 2024. However, the Company is currently forecasting that the summary of key efficacy and safety data will not be available until after June 30, 2024, therefore such subsequent milestone is not expected to be achieved. The PUR1900 Phase 2b study is anticipated to deliver topline data in the third quarter of 2024. Accounting Treatment The Company concluded that because both it and Cipla are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, the Company’s collaboration with Cipla is within the scope of Accounting Standards Codification (“ASC”) 808, Collaborative Arrangements Revenue from Contracts with Customers The Company initially determined the total transaction price to be $ 22.0 12.0 10.0 The Company concluded that the Amendment represented a contract modification that is treated for accounting purposes as the termination of the Cipla Agreement and a creation of a new contract (the “Amended Cipla Agreement”). Accordingly, the modification is accounted for on a prospective basis. The total transaction price for the Amended Cipla Agreement includes variable consideration from the Amendment as well as $ 7.4 Revenue is recognized for the Amended Cipla Agreement as the research and development services are provided using an input method, according to the ratio of costs incurred to the total costs expected to be incurred in the future to satisfy the Company’s obligations. In management’s judgment, this input method is the best measure of the transfer of control of the combined performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company’s consolidated balance sheets, with amounts expected to be recognized in the next 12 months recorded as current. During the three and six months ended June 30, 2023, the Company recognized $ 1.8 3.3 0.3 0.5 5.5 1.1

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Common Stock	8. Common Stock In May 2021, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright and Co., LLC (“HCW”) to act as the Company’s sales agent with respect to the issuance and sale of up to $ 20.0 3.0 During the six months ended June 30, 2023, the Company sold 13,100 4.25 53

Warrants

Warrants	6 Months Ended
	Jun. 30, 2023
Warrants
Warrants	9. Warrants There were no warrants issued or exercised during the six months ended June 30, 2023. Warrants to purchase up to 123,310 149.99 Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 April 8, 2019 $ 26.99 April 8, 2024 65,907 65,907 April 8, 2019 $ 33.74 April 3, 2024 39,871 39,871 February 12, 2019 $ 36.62 February 7, 2024 5,548 5,548 February 12, 2019 $ 26.79 August 12, 2024 66,675 66,675 February 4, 2019 $ 42.49 January 30, 2024 1,732 1,732 January 31, 2019 $ 42.49 January 26, 2024 511 511 December 3, 2018 $ 77.99 June 3, 2024 46,876 46,876 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - 1,161,493 1,145,538

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	10. Stock-based Compensation The Company sponsors the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the “Incentive Plan”). As of June 30, 2023, the Incentive Plan provided for the grant of up to 636,322 239,262 In addition, the Company sponsors two legacy plans under which no additional awards may be granted. As of June 30, 2023, the two legacy plans have a total of 32 The following table summarizes stock option activity for the six months ended June 30, 2023: Summary of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2023 304,823 $ 28.66 7.98 $ - Granted 117,912 $ 3.99 Forfeited or expired (29,481 ) $ 8.90 Outstanding — June 30, 2023 393,254 $ 22.74 8.01 $ - Exercisable — June 30, 2023 196,203 $ 36.88 7.11 $ - The Company records stock-based compensation expense related to stock options based on their grant-date fair value. During the six months ended June 30, 2023 and 2022, the Company used the Black-Scholes option-pricing model to estimate the fair value of stock option grants and to determine the related compensation expense. The assumptions used in calculating the fair value of stock-based payment awards represent management’s best estimates. The weighted-average grant-date fair value of options granted during the six months ended June 30, 2023 was $ 3.27 Schedule of Calculation of Fair Value Assumptions Six Months Ended June 30, 2023 2022 Expected option life (years) 6.0 6.0 Risk-free interest rate 3.53 % 1.74 % Expected volatility 104.30 % 113.59 % Expected dividend yield - % - % The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity. The risk-free interest rate was obtained from U.S. Treasury rates for the expected life of the stock options. The Company’s expected volatility was based upon the weighted average of historical volatility for industry peers and its own volatility. The dividend yield considers that the Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future. As of June 30, 2023, there was $ 1.3 2.1 The following table presents total stock-based compensation expense for the three and six months ended June 30, 2023 and 2022: Schedule of Stock-based Compensation Expenses 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 59 $ 64 $ 131 $ 126 General and administrative 196 213 420 432 Total stock-based compensation expense $ 255 $ 277 $ 551 $ 558

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Research and Development Activities The Company contracts with various other organizations to conduct research and development activities, including clinical trials. As of June 30, 2023, the Company had aggregate commitments to pay approximately $ 4.8 2.3 4.8 4.3 Legal Proceedings In the ordinary course of its business, the Company may be involved in various legal proceedings involving contractual and employment relationships, patent or other intellectual property rights, and a variety of other matters. The Company is not aware of any pending legal proceedings that would reasonably be expected to have a material impact on the Company’s financial position or results of operations.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases
Leases	12. Leases Corporate Headquarters as of June 30, 2023 The Company has limited leasing activities as a lessee which are primarily related to its corporate headquarters. As of June 30, 2023, its corporate headquarters were located at 99 Hayden Avenue, Suite 390, Lexington, Massachusetts. The lease is for approximately 22,000 August 31, 2023 The Company also leases small office equipment which is primarily short-term or immaterial in nature. Therefore, no right-of-use assets and lease liabilities are recognized for these leases. The components of lease expense for the Company for the three and six months ended June 30, 2023 and 2022 were as follows: Schedule of Components of Lease Expenses 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Lease cost Fixed lease cost $ 418 $ 357 $ 796 $ 715 Variable lease cost 168 146 281 350 Total lease cost $ 586 $ 503 $ 1,077 $ 1,065 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 432 $ 308 $ 863 $ 615 Weighted-average remaining lease term — operating leases 0.2 Weighted-average discount rate — operating leases 8.40 % Maturities of lease liabilities due under these lease agreements as of June 30, 2023 are as follows: Schedule of Maturities of Lease Liabilities Operating Leases Maturity of lease liabilities 2023 (two months) $ 359 Total lease payments 359 Less: interest (1 ) Total lease liabilities $ 358 Schedule of Operating Lease Liability Reported as of June 30, 2023 Lease liabilities — short term $ 358 Lease liabilities — long term - Total lease liabilities $ 358 New Corporate Headquarters On January 7, 2022, the Company executed a lease agreement with Cobalt Propco 2020, LLC for its new corporate headquarters at 36 Crosby Drive, Bedford, Massachusetts. As of June 30, 2023, the lease liability and right-of-use asset were not recorded on the consolidated balance sheets as the facility was under construction and the lease commencement date had not yet been reached. Lease commencement occurred in July 2023, following completion of construction to prepare the premises for the Company’s intended use. The leased premises comprise approximately 20,000 lease provides for base rent of $ 0.1 The improvements to prepare the leased premises for the Company’s intended use have been funded by (i) the landlord through a tenant allowance of $ 3.9 0.5 3.4 The Company has made $ 1.7

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company had no income tax expense due to operating losses incurred for the three and six months ended June 30, 2023 and 2022. Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance was recorded as of June 30, 2023 and December 31, 2022. The Company applies ASC 740, Income Taxes

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	14. Net Loss Per Share Basic and diluted earnings (loss) per share are computed using the two-class method, which is an earnings allocation method that determines earnings (loss) per share for common shares and participating securities. The participating securities consist of the Company’s Series A Preferred Stock. The undistributed earnings are allocated between common shares and participating securities as if all earnings had been distributed during the period. In periods of loss, no allocation is made to the Series A Preferred Stock and diluted net loss per share is the same as basic net loss per share because common stock equivalents are excluded as their inclusion would be antidilutive. The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three and Six Months Ended June 30, 2023 2022 Options to purchase common stock 393,254 286,565 Warrants to purchase common stock 1,161,493 1,284,803 1,554,747 1,571,368

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events The Company has completed an evaluation of all subsequent events after the balance sheet date of June 30, 2023 through the date the condensed consolidated financial statements were issued to ensure that the condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of June 30, 2023, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. The Company has concluded that no subsequent events have occurred that require disclosure, except as disclosed within the condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Recent Accounting Standards (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 30, 2023 (the “Annual Report”). The financial information as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022, is unaudited. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The balance sheet data as of December 31, 2022 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
Use of Estimates	Use of Estimates In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, incremental borrowing rate, and accounting for income taxes and the related valuation allowance.
Concentrations of Credit Risk	Concentrations of Credit Risk Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits. For the three and six months ended June 30, 2023, revenue from one customer accounted for 100 99 100
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as set forth below, the Company did not adopt any new accounting pronouncements during the six months ended June 30, 2023 that had a material effect on its condensed consolidated financial statements. In June 2016, the FASB issued Accounting Standards Update (“ASU”) ASU 2016-13, Financial Instruments—Credit Losses (Topic 326)—Measurement of Credit Losses on Financial Instruments January 1, 2023 As of June 30, 2023, there are no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated financial statements.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: Schedule of Prepaid Expenses and Other Current Assets June 30, 2023 December 31, 2022 Insurance $ 496 $ 286 Clinical and consulting 132 517 Software and hosting costs 119 99 Other 272 166 Total prepaid expenses and other current assets $ 1,019 $ 1,068

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: Schedule of Property and Equipment June 30, 2023 December 31, 2022 Laboratory equipment $ 1,835 $ 1,827 Leasehold improvements 664 664 Computer equipment 262 275 Office furniture and equipment 217 217 Capital in progress 100 - Total property and equipment 3,078 2,983 Less accumulated depreciation and amortization (2,799 ) (2,748 ) Property and equipment, net $ 279 $ 235

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities June 30, 2023 December 31, 2022 Wages and incentives $ 746 $ 1,130 Clinical and consulting 287 475 Legal and patents 74 - Other 94 33 Total accrued expenses and other current liabilities $ 1,201 $ 1,638

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2023
Warrants
Schedule of Warrants Outstanding	Schedule of Warrants Outstanding Adjusted Number of Shares Issue Date Exercise Price Expiration Date Outstanding Exercisable December 17, 2021 $ 14.99 December 15, 2026 36,538 36,538 December 17, 2021 $ 13.99 December 17, 2026 281,047 281,047 February 16, 2021 $ 49.99 February 11, 2026 65,003 65,003 August 7, 2020 $ 35.99 July 14, 2025 90,743 90,743 August 7, 2020 $ 44.99 July 14, 2025 10,939 10,939 July 23, 2020 $ 35.99 July 14, 2025 77,502 77,502 July 13, 2020 $ 44.99 July 14, 2025 21,846 21,846 July 13, 2020 $ 35.99 July 14, 2025 334,800 334,800 April 8, 2019 $ 26.99 April 8, 2024 65,907 65,907 April 8, 2019 $ 33.74 April 3, 2024 39,871 39,871 February 12, 2019 $ 36.62 February 7, 2024 5,548 5,548 February 12, 2019 $ 26.79 August 12, 2024 66,675 66,675 February 4, 2019 $ 42.49 January 30, 2024 1,732 1,732 January 31, 2019 $ 42.49 January 26, 2024 511 511 December 3, 2018 $ 77.99 June 3, 2024 46,876 46,876 June 15, 2015 $ 1,509.99 Five years after milestone achievement 15,955 - 1,161,493 1,145,538

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity for the six months ended June 30, 2023: Summary of Stock Option Activity Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — January 1, 2023 304,823 $ 28.66 7.98 $ - Granted 117,912 $ 3.99 Forfeited or expired (29,481 ) $ 8.90 Outstanding — June 30, 2023 393,254 $ 22.74 8.01 $ - Exercisable — June 30, 2023 196,203 $ 36.88 7.11 $ -
Schedule of Calculation of Fair Value Assumptions	Schedule of Calculation of Fair Value Assumptions Six Months Ended June 30, 2023 2022 Expected option life (years) 6.0 6.0 Risk-free interest rate 3.53 % 1.74 % Expected volatility 104.30 % 113.59 % Expected dividend yield - % - %
Schedule of Stock-based Compensation Expenses	The following table presents total stock-based compensation expense for the three and six months ended June 30, 2023 and 2022: Schedule of Stock-based Compensation Expenses 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 59 $ 64 $ 131 $ 126 General and administrative 196 213 420 432 Total stock-based compensation expense $ 255 $ 277 $ 551 $ 558

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases
Schedule of Components of Lease Expenses	The components of lease expense for the Company for the three and six months ended June 30, 2023 and 2022 were as follows: Schedule of Components of Lease Expenses 2023 2022 2023 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Lease cost Fixed lease cost $ 418 $ 357 $ 796 $ 715 Variable lease cost 168 146 281 350 Total lease cost $ 586 $ 503 $ 1,077 $ 1,065 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 432 $ 308 $ 863 $ 615 Weighted-average remaining lease term — operating leases 0.2 Weighted-average discount rate — operating leases 8.40 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities due under these lease agreements as of June 30, 2023 are as follows: Schedule of Maturities of Lease Liabilities Operating Leases Maturity of lease liabilities 2023 (two months) $ 359 Total lease payments 359 Less: interest (1 ) Total lease liabilities $ 358
Schedule of Operating Lease Liability	Schedule of Operating Lease Liability Reported as of June 30, 2023 Lease liabilities — short term $ 358 Lease liabilities — long term - Total lease liabilities $ 358

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact: Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding Three and Six Months Ended June 30, 2023 2022 Options to purchase common stock 393,254 286,565 Warrants to purchase common stock 1,161,493 1,284,803 1,554,747 1,571,368

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Recent Accounting Standards (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accounting Standards Update 2016-13 [Member]
Product Information [Line Items]
Adoption date	Jan. 01, 2023		Jan. 01, 2023
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage	100%	99%	100%	99%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage			100%		100%

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Insurance	$ 496	$ 286
Clinical and consulting	132	517
Software and hosting costs	119	99
Other	272	166
Total prepaid expenses and other current assets	$ 1,019	$ 1,068

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 3,078	$ 2,983
Less accumulated depreciation and amortization	(2,799)	(2,748)
Property and equipment, net	279	235
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	1,835	1,827
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	664	664
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	262	275
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	217	217
Capital In Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 100

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 64	$ 81

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Wages and incentives	$ 746	$ 1,130
Clinical and consulting	287	475
Legal and patents	74
Other	94	33
Total accrued expenses and other current liabilities	$ 1,201	$ 1,638

Significant Agreements (Details

Significant Agreements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Product Liability Contingency [Line Items]
Agreement description			Pursuant to the Amendment, the Company and Cipla will each initially be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). Upon the achievement of each development milestone set forth in the table below, Cipla will reimburse the Company an amount equal to 10% of the cumulative aggregate Direct Costs incurred (each reimbursement referred to as a “Holdback Payment”), potentially bringing the sharing of Direct Costs to a 50/50 basis. If a development milestone is not achieved, the respective Holdback Payment will continue to aggregate and be reimbursed by Cipla to the Company if the Company achieves the subsequent development milestone for that trial set forth in the table below. The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
Transaction cost	$ 22,000		$ 22,000
Revenue	1,844	$ 1,331	3,343	$ 2,491
Deferred revenue, current	1,109		1,109		$ 1,339
Cipla Agreement [Member] | Cipla Technologies LLC [Member]
Product Liability Contingency [Line Items]
Proceeds from related party debt			22,000
Transaction price			7,400
Deferred revenue	300		500
Deferred revenue	5,500		5,500
Deferred revenue, current	1,100		1,100
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]
Product Liability Contingency [Line Items]
Transaction cost	12,000		12,000
Revenue	1,800		3,300
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]
Product Liability Contingency [Line Items]
Transaction cost	$ 10,000		$ 10,000

Common Stock (Details Narrative

Common Stock (Details Narrative) - H.C.Wainwright and Co., LLC [Member] - Sale Agreement [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	May 31, 2021	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, consideration received on transaction	$ 20,000
Commission percentage	3%
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued in transaction		13,100
Sale of stock, price per share		$ 4.25
Sale of stock, consideration received per transaction		$ 53

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 14.99
Warrants, Expiration Date	Dec. 15, 2026
Number of Shares Underlying Warrants, Outstanding	36,538
Number of Shares Underlying Warrants, Exercisable	36,538
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 17, 2021
Warrants, Exercise Price | $ / shares	$ 13.99
Warrants, Expiration Date	Dec. 17, 2026
Number of Shares Underlying Warrants, Outstanding	281,047
Number of Shares Underlying Warrants, Exercisable	281,047
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 16, 2021
Warrants, Exercise Price | $ / shares	$ 49.99
Warrants, Expiration Date	Feb. 11, 2026
Number of Shares Underlying Warrants, Outstanding	65,003
Number of Shares Underlying Warrants, Exercisable	65,003
Warrant Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding	90,743
Number of Shares Underlying Warrants, Exercisable	90,743
Warrant Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Aug. 07, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding	10,939
Number of Shares Underlying Warrants, Exercisable	10,939
Warrant Six [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 23, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding	77,502
Number of Shares Underlying Warrants, Exercisable	77,502
Warrant Seven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 44.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding	21,846
Number of Shares Underlying Warrants, Exercisable	21,846
Warrant Eight [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jul. 13, 2020
Warrants, Exercise Price | $ / shares	$ 35.99
Warrants, Expiration Date	Jul. 14, 2025
Number of Shares Underlying Warrants, Outstanding	334,800
Number of Shares Underlying Warrants, Exercisable	334,800
Warrant Nine [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Apr. 08, 2019
Warrants, Exercise Price | $ / shares	$ 26.99
Warrants, Expiration Date	Apr. 08, 2024
Number of Shares Underlying Warrants, Outstanding	65,907
Number of Shares Underlying Warrants, Exercisable	65,907
Warrant Ten [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Apr. 08, 2019
Warrants, Exercise Price | $ / shares	$ 33.74
Warrants, Expiration Date	Apr. 03, 2024
Number of Shares Underlying Warrants, Outstanding	39,871
Number of Shares Underlying Warrants, Exercisable	39,871
Warrant Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 12, 2019
Warrants, Exercise Price | $ / shares	$ 36.62
Warrants, Expiration Date	Feb. 07, 2024
Number of Shares Underlying Warrants, Outstanding	5,548
Number of Shares Underlying Warrants, Exercisable	5,548
Warrant Twelve [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 12, 2019
Warrants, Exercise Price | $ / shares	$ 26.79
Warrants, Expiration Date	Aug. 12, 2024
Number of Shares Underlying Warrants, Outstanding	66,675
Number of Shares Underlying Warrants, Exercisable	66,675
Warrant Thirteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Feb. 04, 2019
Warrants, Exercise Price | $ / shares	$ 42.49
Warrants, Expiration Date	Jan. 30, 2024
Number of Shares Underlying Warrants, Outstanding	1,732
Number of Shares Underlying Warrants, Exercisable	1,732
Warrant Fourteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jan. 31, 2019
Warrants, Exercise Price | $ / shares	$ 42.49
Warrants, Expiration Date	Jan. 26, 2024
Number of Shares Underlying Warrants, Outstanding	511
Number of Shares Underlying Warrants, Exercisable	511
Warrant Fifteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Dec. 03, 2018
Warrants, Exercise Price | $ / shares	$ 77.99
Warrants, Expiration Date	Jun. 03, 2024
Number of Shares Underlying Warrants, Outstanding	46,876
Number of Shares Underlying Warrants, Exercisable	46,876
Warrant Eighteen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, Issue Date	Jun. 15, 2015
Warrants, Exercise Price | $ / shares	$ 1,509.99
Number of Shares Underlying Warrants, Outstanding	15,955
Number of Shares Underlying Warrants, Exercisable
Warrants, Expiration Date, Description	Five years after milestone achievement
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Underlying Warrants, Outstanding	1,161,493
Number of Shares Underlying Warrants, Exercisable	1,145,538

Warrants (Details Narrative)

Warrants (Details Narrative)	6 Months Ended
	Jun. 30, 2023 shares
Warrants
Warrants expired shares	123,310
Warrants expired per shares	149.99

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - Equity Option [Member]	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Offsetting Assets [Line Items]
Number of Options, Outstanding, Balance | shares	304,823
Weighted Average Exercise Price, Outstanding, Balance | $ / shares	$ 28.66
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years 11 months 23 days
Aggregate Intrinsic Value, Balance | $
Number of Options, Granted | shares	117,912
Weighted Average Exercise Price, Granted | $ / shares	$ 3.99
Number of Options, Forfeited or expired | shares	(29,481)
Weighted Average Exercise Price, Forfeited or expired | $ / shares	$ 8.90
Number of Options, Outstanding, Balance | shares	393,254
Weighted Average Exercise Price, Outstanding, Balance | $ / shares	$ 22.74
Weighted Average Remaining Contractual Term (Years), Outstanding	8 years 3 days
Aggregate Intrinsic Value, Balance | $
Number of Options, Exercisable | shares	196,203
Weighted Average Exercise Price, Outstanding, Exercisable | $ / shares	$ 36.88
Weighted Average Remaining Contractual Term (Years), Exercisable	7 years 1 month 9 days
Aggregate Intrinsic Value, Exercisable | $

Schedule of Calculation of Fair

Schedule of Calculation of Fair Value Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected option life (years)		6 years	6 years
Risk-free interest rate		3.53%	1.74%
Expected volatility		104.30%	113.59%
Expected dividend yield

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 255	$ 277	$ 551	$ 558
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	59	64	131	126
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 196	$ 213	$ 420	$ 432

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Valuation Technique, Option Pricing Model [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value of options | $ / shares	$ 3.27
Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, number of shares authorized	636,322
Share based compensation arrangement, number of shares available for grant	239,262
Legacy Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement, award options outstanding number	32
Stock Award Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation expenses | $	$ 1.3
Weighted-average period of unrecognized stock-based compensation expense	2 years 1 month 6 days

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Payments for research and development	$ 4.8
Expects to be reimbursed	2.3
Commitments	4.8
Commitment, due in twelve months	$ 4.3

Schedule of Components of Lease

Schedule of Components of Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lease cost
Fixed lease cost	$ 418	$ 357	$ 796	$ 715
Variable lease cost	168	146	281	350
Total lease cost	586	503	1,077	1,065
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 432	$ 308	$ 863	$ 615
Weighted-average discount rate - operating leases	2 months 12 days		2 months 12 days
Weighted-average discount rate - operating leases	8.40%		8.40%

Schedule of Maturities of Lease

Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Maturity of lease liabilities
2023 (two months)	$ 359
Total lease payments	359
Less: interest	(1)
Total lease liabilities	$ 358

Schedule of Operating Lease Lia

Schedule of Operating Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases
Lease liabilities — short term	$ 358	$ 857
Lease liabilities — long term
Total lease liabilities	$ 358

Leases (Details Narrative)

Leases (Details Narrative) $ in Millions		6 Months Ended
	Jan. 07, 2022 USD ($) ft²	Jun. 30, 2023 USD ($) ft²
Area of land | ft²		22,000
Payments to leasehold improvements		$ 1.7
Lease Agreement [Member] | Cobalt Propco [Member]
Area of land | ft²	20,000
Lessee, operating lease, description	lease provides for base rent of $0.1 million per month, expected to begin in the fourth quarter of 2023, which will increase 3% each year over the ten-year noncancellable term. The Company has the option to extend the lease for one additional five-year term and is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.
Payments for rent	$ 0.1
Payments for tenant improvements	3.9
Tenat improvements	0.5
Proceeds from affiliates	$ 3.4
Hayden LLC [Member]
Lease expiration date		Aug. 31, 2023

Schedule of Computation of Anti

Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares outstanding	1,554,747	1,571,368	1,554,747	1,571,368
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares outstanding	393,254	286,565	393,254	286,565
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares outstanding	1,161,493	1,284,803	1,161,493	1,284,803